Effect of retinoic acid in experimental diabetic nephropathy

Sang Youb Han, Gyeong A. So, Yi Hwa Jee, Kum Hyun Han, Young Sun Kang, Hyoung Kyu Kim, Shin Wook Kang, Dae Suk Han, Jee Young Han, Dae-Ryong Cha

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Although the pathogenetic mechanism of diabetic nephropathy has not been elucidated, an inflammatory mechanism has been suggested to contribute to its progression. Monocyte chemoattractant peptide (MCP)-1 attracts macrophages and T cells, and ultimately injures renal tissue. In early diabetic nephropathy, urinary excretion of MCP-1 was elevated, and increased as renal damage became more severe. Podocytes are expected to have an inflammatory role in diabetic nephropathy, as the surface expression of chemokine receptors such as CCR and CXCR on these cells has been recently reported. Although retinoid (retinal), a known anti-inflammatory agent, has been reported to be beneficial in some experimental models of renal disease, it has not been determined to prevent disease progression in diabetic nephropathy. We investigated the effects of all-trans retinoic acid on the production of MCP-1 under high glucose conditions in cultured mouse podocytes. We also evaluated whether all-trans retinoic acid inhibits inflammatory changes and improves renal function during the early stages of diabetic nephropathy in streptozotocin-induced diabetic rats. In cultured podocytes, high glucose stimuli rapidly upregulated the MCP-1 mRNA transcript and protein release. Treatment with retinoic acid tended to suppress the MCP-1 gene transcript, and significantly inhibited MCP-1 protein synthesis induced by high glucose stimulation. Urinary protein excretion and the urinary albumin: creatinine ratio (ACR) were significantly higher in diabetic rats 4 weeks after the induction of diabetes mellitus compared with control rats, and retinoic acid treatment markedly decreased both proteinuria and urinary ACR (proteinuria: 1.25 ± 0.69 vs 0.78 ± 0.72 mg/mgCr, P = 0.056; urinary ACR: 0.47 ± 0.25 vs 0.21 ± 0.06 mg/mgCr, P = 0.088). Urinary excretion of MCP-1 was rapidly increased 2 days after induction of diabetes mellitus in diabetic rats, and further increased until rats were 4 weeks of age, compared with control rats. Retinoic acid treatment resulted in 30% reduction of the urinary level of MCP-1 compared with vehicle-treated diabetic rats (119.3 ± 74.2 vs 78.1 ± 62.7 pg/mgCr, P = 0.078). Immunohistochemistry revealed a significant increase in staining for MCP-1 and anti-monocyte/macrophage (ED-1) protein in the diabetic kidney, and retinoic acid treatment significantly suppressed intrarenal MCP-1 and ED-1 protein synthesis. In conclusion, podocytes are involved in the inflammatory reaction under diabetic circumstances, and these reactions were suppressed by retinoic acid. Retinoic acid also suppressed inflammatory changes in the diabetic rat kidney, and decreased proteinuria in diabetic rats. These results suggest that retinoic acid may have renoprotective effects in the early stages of diabetic nephropathy through an anti-inflammatory activity.

Original languageEnglish
Pages (from-to)568-576
Number of pages9
JournalImmunology and Cell Biology
Volume82
Issue number6
DOIs
Publication statusPublished - 2004 Dec 1

Fingerprint

Chemotactic Factors
Diabetic Nephropathies
Tretinoin
Monocytes
Peptides
Rats
Podocytes
Kidney
Proteinuria
Rat control
Albumins
Creatinine
Macrophages
Medical problems
Proteins
Glucose
Diabetes Mellitus
Anti-Inflammatory Agents
T-cells
Chemokine CCL2

Keywords

  • Diabetic nephropathy
  • Inflammation
  • Monocyte chemoattractant peptide (MCP)-1
  • Podocyte
  • Retinoid
  • Streptozotocin

ASJC Scopus subject areas

  • Immunology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Effect of retinoic acid in experimental diabetic nephropathy. / Han, Sang Youb; So, Gyeong A.; Jee, Yi Hwa; Han, Kum Hyun; Kang, Young Sun; Kim, Hyoung Kyu; Kang, Shin Wook; Han, Dae Suk; Han, Jee Young; Cha, Dae-Ryong.

In: Immunology and Cell Biology, Vol. 82, No. 6, 01.12.2004, p. 568-576.

Research output: Contribution to journalArticle

Han, SY, So, GA, Jee, YH, Han, KH, Kang, YS, Kim, HK, Kang, SW, Han, DS, Han, JY & Cha, D-R 2004, 'Effect of retinoic acid in experimental diabetic nephropathy', Immunology and Cell Biology, vol. 82, no. 6, pp. 568-576. https://doi.org/10.1111/j.1440-1711.2004.01287.x
Han, Sang Youb ; So, Gyeong A. ; Jee, Yi Hwa ; Han, Kum Hyun ; Kang, Young Sun ; Kim, Hyoung Kyu ; Kang, Shin Wook ; Han, Dae Suk ; Han, Jee Young ; Cha, Dae-Ryong. / Effect of retinoic acid in experimental diabetic nephropathy. In: Immunology and Cell Biology. 2004 ; Vol. 82, No. 6. pp. 568-576.
@article{a4e976ddb46b4c5997836952838afeb4,
title = "Effect of retinoic acid in experimental diabetic nephropathy",
abstract = "Although the pathogenetic mechanism of diabetic nephropathy has not been elucidated, an inflammatory mechanism has been suggested to contribute to its progression. Monocyte chemoattractant peptide (MCP)-1 attracts macrophages and T cells, and ultimately injures renal tissue. In early diabetic nephropathy, urinary excretion of MCP-1 was elevated, and increased as renal damage became more severe. Podocytes are expected to have an inflammatory role in diabetic nephropathy, as the surface expression of chemokine receptors such as CCR and CXCR on these cells has been recently reported. Although retinoid (retinal), a known anti-inflammatory agent, has been reported to be beneficial in some experimental models of renal disease, it has not been determined to prevent disease progression in diabetic nephropathy. We investigated the effects of all-trans retinoic acid on the production of MCP-1 under high glucose conditions in cultured mouse podocytes. We also evaluated whether all-trans retinoic acid inhibits inflammatory changes and improves renal function during the early stages of diabetic nephropathy in streptozotocin-induced diabetic rats. In cultured podocytes, high glucose stimuli rapidly upregulated the MCP-1 mRNA transcript and protein release. Treatment with retinoic acid tended to suppress the MCP-1 gene transcript, and significantly inhibited MCP-1 protein synthesis induced by high glucose stimulation. Urinary protein excretion and the urinary albumin: creatinine ratio (ACR) were significantly higher in diabetic rats 4 weeks after the induction of diabetes mellitus compared with control rats, and retinoic acid treatment markedly decreased both proteinuria and urinary ACR (proteinuria: 1.25 ± 0.69 vs 0.78 ± 0.72 mg/mgCr, P = 0.056; urinary ACR: 0.47 ± 0.25 vs 0.21 ± 0.06 mg/mgCr, P = 0.088). Urinary excretion of MCP-1 was rapidly increased 2 days after induction of diabetes mellitus in diabetic rats, and further increased until rats were 4 weeks of age, compared with control rats. Retinoic acid treatment resulted in 30{\%} reduction of the urinary level of MCP-1 compared with vehicle-treated diabetic rats (119.3 ± 74.2 vs 78.1 ± 62.7 pg/mgCr, P = 0.078). Immunohistochemistry revealed a significant increase in staining for MCP-1 and anti-monocyte/macrophage (ED-1) protein in the diabetic kidney, and retinoic acid treatment significantly suppressed intrarenal MCP-1 and ED-1 protein synthesis. In conclusion, podocytes are involved in the inflammatory reaction under diabetic circumstances, and these reactions were suppressed by retinoic acid. Retinoic acid also suppressed inflammatory changes in the diabetic rat kidney, and decreased proteinuria in diabetic rats. These results suggest that retinoic acid may have renoprotective effects in the early stages of diabetic nephropathy through an anti-inflammatory activity.",
keywords = "Diabetic nephropathy, Inflammation, Monocyte chemoattractant peptide (MCP)-1, Podocyte, Retinoid, Streptozotocin",
author = "Han, {Sang Youb} and So, {Gyeong A.} and Jee, {Yi Hwa} and Han, {Kum Hyun} and Kang, {Young Sun} and Kim, {Hyoung Kyu} and Kang, {Shin Wook} and Han, {Dae Suk} and Han, {Jee Young} and Dae-Ryong Cha",
year = "2004",
month = "12",
day = "1",
doi = "10.1111/j.1440-1711.2004.01287.x",
language = "English",
volume = "82",
pages = "568--576",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of retinoic acid in experimental diabetic nephropathy

AU - Han, Sang Youb

AU - So, Gyeong A.

AU - Jee, Yi Hwa

AU - Han, Kum Hyun

AU - Kang, Young Sun

AU - Kim, Hyoung Kyu

AU - Kang, Shin Wook

AU - Han, Dae Suk

AU - Han, Jee Young

AU - Cha, Dae-Ryong

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Although the pathogenetic mechanism of diabetic nephropathy has not been elucidated, an inflammatory mechanism has been suggested to contribute to its progression. Monocyte chemoattractant peptide (MCP)-1 attracts macrophages and T cells, and ultimately injures renal tissue. In early diabetic nephropathy, urinary excretion of MCP-1 was elevated, and increased as renal damage became more severe. Podocytes are expected to have an inflammatory role in diabetic nephropathy, as the surface expression of chemokine receptors such as CCR and CXCR on these cells has been recently reported. Although retinoid (retinal), a known anti-inflammatory agent, has been reported to be beneficial in some experimental models of renal disease, it has not been determined to prevent disease progression in diabetic nephropathy. We investigated the effects of all-trans retinoic acid on the production of MCP-1 under high glucose conditions in cultured mouse podocytes. We also evaluated whether all-trans retinoic acid inhibits inflammatory changes and improves renal function during the early stages of diabetic nephropathy in streptozotocin-induced diabetic rats. In cultured podocytes, high glucose stimuli rapidly upregulated the MCP-1 mRNA transcript and protein release. Treatment with retinoic acid tended to suppress the MCP-1 gene transcript, and significantly inhibited MCP-1 protein synthesis induced by high glucose stimulation. Urinary protein excretion and the urinary albumin: creatinine ratio (ACR) were significantly higher in diabetic rats 4 weeks after the induction of diabetes mellitus compared with control rats, and retinoic acid treatment markedly decreased both proteinuria and urinary ACR (proteinuria: 1.25 ± 0.69 vs 0.78 ± 0.72 mg/mgCr, P = 0.056; urinary ACR: 0.47 ± 0.25 vs 0.21 ± 0.06 mg/mgCr, P = 0.088). Urinary excretion of MCP-1 was rapidly increased 2 days after induction of diabetes mellitus in diabetic rats, and further increased until rats were 4 weeks of age, compared with control rats. Retinoic acid treatment resulted in 30% reduction of the urinary level of MCP-1 compared with vehicle-treated diabetic rats (119.3 ± 74.2 vs 78.1 ± 62.7 pg/mgCr, P = 0.078). Immunohistochemistry revealed a significant increase in staining for MCP-1 and anti-monocyte/macrophage (ED-1) protein in the diabetic kidney, and retinoic acid treatment significantly suppressed intrarenal MCP-1 and ED-1 protein synthesis. In conclusion, podocytes are involved in the inflammatory reaction under diabetic circumstances, and these reactions were suppressed by retinoic acid. Retinoic acid also suppressed inflammatory changes in the diabetic rat kidney, and decreased proteinuria in diabetic rats. These results suggest that retinoic acid may have renoprotective effects in the early stages of diabetic nephropathy through an anti-inflammatory activity.

AB - Although the pathogenetic mechanism of diabetic nephropathy has not been elucidated, an inflammatory mechanism has been suggested to contribute to its progression. Monocyte chemoattractant peptide (MCP)-1 attracts macrophages and T cells, and ultimately injures renal tissue. In early diabetic nephropathy, urinary excretion of MCP-1 was elevated, and increased as renal damage became more severe. Podocytes are expected to have an inflammatory role in diabetic nephropathy, as the surface expression of chemokine receptors such as CCR and CXCR on these cells has been recently reported. Although retinoid (retinal), a known anti-inflammatory agent, has been reported to be beneficial in some experimental models of renal disease, it has not been determined to prevent disease progression in diabetic nephropathy. We investigated the effects of all-trans retinoic acid on the production of MCP-1 under high glucose conditions in cultured mouse podocytes. We also evaluated whether all-trans retinoic acid inhibits inflammatory changes and improves renal function during the early stages of diabetic nephropathy in streptozotocin-induced diabetic rats. In cultured podocytes, high glucose stimuli rapidly upregulated the MCP-1 mRNA transcript and protein release. Treatment with retinoic acid tended to suppress the MCP-1 gene transcript, and significantly inhibited MCP-1 protein synthesis induced by high glucose stimulation. Urinary protein excretion and the urinary albumin: creatinine ratio (ACR) were significantly higher in diabetic rats 4 weeks after the induction of diabetes mellitus compared with control rats, and retinoic acid treatment markedly decreased both proteinuria and urinary ACR (proteinuria: 1.25 ± 0.69 vs 0.78 ± 0.72 mg/mgCr, P = 0.056; urinary ACR: 0.47 ± 0.25 vs 0.21 ± 0.06 mg/mgCr, P = 0.088). Urinary excretion of MCP-1 was rapidly increased 2 days after induction of diabetes mellitus in diabetic rats, and further increased until rats were 4 weeks of age, compared with control rats. Retinoic acid treatment resulted in 30% reduction of the urinary level of MCP-1 compared with vehicle-treated diabetic rats (119.3 ± 74.2 vs 78.1 ± 62.7 pg/mgCr, P = 0.078). Immunohistochemistry revealed a significant increase in staining for MCP-1 and anti-monocyte/macrophage (ED-1) protein in the diabetic kidney, and retinoic acid treatment significantly suppressed intrarenal MCP-1 and ED-1 protein synthesis. In conclusion, podocytes are involved in the inflammatory reaction under diabetic circumstances, and these reactions were suppressed by retinoic acid. Retinoic acid also suppressed inflammatory changes in the diabetic rat kidney, and decreased proteinuria in diabetic rats. These results suggest that retinoic acid may have renoprotective effects in the early stages of diabetic nephropathy through an anti-inflammatory activity.

KW - Diabetic nephropathy

KW - Inflammation

KW - Monocyte chemoattractant peptide (MCP)-1

KW - Podocyte

KW - Retinoid

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=9444258635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444258635&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1711.2004.01287.x

DO - 10.1111/j.1440-1711.2004.01287.x

M3 - Article

C2 - 15550114

AN - SCOPUS:9444258635

VL - 82

SP - 568

EP - 576

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 6

ER -